PDB Reference: synthetase domain of human CTPS, 2c5m, r2c5msf.
Figure 1
The overall reaction catalysed by CTPS. Phosphate is transferred from ATP to the O4 of UTP and the ammonium ion obtained from glutamine is then used to replace the phosphate to generate CTP. R = ribose-5 0 -triphosphate. Meinsma et al., 2000) and antiparasitic (Hofer et al., 2001) drug development. CTPS activity is also increased in a variety of human cancers (Williams et al., 1978; Verschuur, Van Gennip, Leen, Meinsma et al., 2000) . Antiproliferative drugs targeted specifically towards human CTPS have been developed, with the aim of depleting cancer cells of CTP and thus slowing down tumour growth (Politi et al., 1995) . Cyclopentenyl cytosine (CPEC), acivicin and 3-deazauridine are CTPS-directed drugs that slow down or arrest the proliferation of tumour cells (Hindenburg et al., 1985; Kang et al., 1989; Zhang et al., 1993; Verschuur, Van Gennip, Leen, Muller et al., 2000) . Resistance to some of these drugs is caused by mutations in CTPS (Whelan et al., 1993) .
The crystal structures of CTPS are known from Thermus thermophilus (Goto et al., 2004) and E. coli (Endrizzi et al., 2004) , and based on these structures, together with other studies, the active site and the substrate-binding modes have been identified. Active CTPS is a homotetramer and the oligomeric state is regulated by nucleotides (Pappas et al., 1998) . However, experimental three-dimensional structures have not been available of CTPS from other organisms, including mammals.
We have determined the crystal structure of the synthetase domain from human CTPS. The structure is homotetrameric and the active site has two bound sulfate ions which indicate the positions of the phosphate moieties of the substrates ATP and UTP. The structure should also provide a structural basis for drug development with the aim of effectively inhibiting CTPS activity in cancer cells.
Materials and methods

Cloning and expression
The cDNA encoding the synthetase domain of human CTPS (isoform 1) was subcloned into the pNIC-Bsa4 vector; the resulting construct codes for a protein with an N-terminal hexahistidine tag with an integrated TEV protease-cleavage site. The sequence of the N-terminal tag was MHHHHHHSSGVDLGTENLYFQS. The plasmid was transformed into BL21(DE3)-Gold cells containing the chaperone plasmid pG-Tf2 (Takara).
Colonies were grown in 20 ml Terrific Broth supplemented with 8 g l À1 glycerol, 50 mg ml À1 kanamycin and 34 mg ml À1 chloramphenicol at 303 K overnight. The following morning, the overnight cultures were diluted into 1500 ml Terrific Broth containing 8 g l À1 glycerol and 50 mg ml À1 kanamycin in TunAir flasks. Cells were grown at 310 K until an OD 600 of 1.4 was reached. 20 min later, induction of chaperone expression was performed with tetracycline (2 ng ml À1 ) and cultures were cooled to 291 K. Target-protein expression was then induced overnight with 0.5 mM IPTG.
Cells were harvested by centrifugation and pellets were suspended in 50 mM sodium phosphate pH 7.5, 500 mM NaCl and 10% glycerol supplemented with one tablet of Complete EDTA-free proteaseinhibitor tablet (Roche) per cell pellet and frozen at 193 K. The cells were briefly thawed in warm water and 1000 U benzonase was added. Cells were disrupted by high-pressure homogenization at 69 MPa and the samples were centrifuged for 20 min at 40 000g. The soluble fraction was filtered prior to further purification.
Purification and crystallization
Purification was conducted on an Ä KTA Xpress system. HisTrap HP and Superdex 75 columns were equilibrated with IMAC buffer 1 [50 mM sodium phosphate pH 7.5, 10 mM imidazole, 500 mM NaCl, 10% glycerol, 0.5 mM Tris(2-carboxyethyl)phosphine (TCEP)] and gel-filtration buffer (20 mM HEPES pH 7.5, 300 mM NaCl, 10% glycerol, 0.5 mM TCEP), respectively. The protein sample was loaded onto the HisTrap HP column, which was washed with IMAC buffer 1 followed by IMAC buffer 2 (50 mM sodium phosphate pH 7.5, 50 mM imidazole, 500 mM NaCl, 10% glycerol, 0.5 mM TCEP). Bound protein was eluted from the HisTrap columns with 7.5 ml IMAC elution buffer (50 mM sodium phosphate pH 7.5, 400 mM imidazole, 500 mM NaCl, 10% glycerol, 0.5 mM TCEP) and loaded onto the gel-filtration column; elution was performed using the gelfiltration buffer. The chromatogram from gel filtration showed one major protein peak, corresponding to a CTPS monomer, that consisted of highly pure human CTPS as shown by SDS-PAGE (not shown). TCEP was added to the pooled protein peak to a final concentration of 2 mM. The protein was concentrated to 5 mg ml À1 and stored at 193 K. The protein was crystallized by the hanging-drop method, equilibrating 1 ml protein solution and 1 ml of a solution containing 0.1 M Tris pH 8.8, 1.2 M (NH 4 ) 2 SO 4 and 50 mM malonic acid against 0.5 ml of a well solution containing 0.1 M Tris pH 8.8 and 1.2 M (NH 4 ) 2 SO 4 . Crystals with a maximum dimension of 30 mm formed in 3 d. Prior to data collection, a crystal was briefly soaked in a cryoprotectant solution [0.1 M Tris pH 8.8, 1.4 M (NH 4 ) 2 SO 4 , 50 mM malonic acid, 25% glycerol, 0.2 M NaCl, 2 mM TCEP].
Data collection and structure solution
Data from cryocooled (100 K) crystals were collected at ESRF beamline ID29 using an ADSC Quantum 210 detector and 1 oscillations per image. The data were processed with MOSFLM (Leslie, 1992) and SCALA (Evans, 2006) . The data-processing statistics are presented in Table 1 perfectly twinned (twinning fraction 50%) with operator k, h, Àl; the apparent space group was P4 1 2 1 2 instead of the true space group P4 1 . The structure was solved by molecular replacement using one monomer from the structure of E. coli CTPS (PDB code 1s1m; Endrizzi et al., 2004) as a model. Firstly, the data were processed in the apparent space group P4 1 2 1 2. Molecular replacement with MOLREP (Vagin & Teplyakov, 1997 ) was then carried out to a highresolution limit of 3 Å . Two monomers were found with an R factor of 51.3% and a correlation coefficient of 40.4%. The R factor fell to 46% during rigid-body refinement in REFMAC (Murshudov et al., 1997) ; after restrained refinement in REFMAC, the R and R free values stopped at 29.8 and 39.0%, respectively. At this point, the twinning was identified and the data were rescaled in space group P4 1 . Molecular replacement in MOLREP with the dimeric model refined in space group P4 1 2 1 2 was carried out, resulting in a tetramer with an R factor of 46.0% and a correlation coefficient of 56.7%. From then on, the structure was refined using CNS (Brü nger et al., 1998) using the scripts for twinned data. Individual B factors for all atoms were refined and water molecules were added using the default parameters in CNS. Seven sulfate ions per asymmetric unit were clearly identified by their shape in the electron density after refinement and were included when their electron density was unambiguous. Model building was carried out in COOT (Emsley & Cowtan, 2004) . The refinement statistics are given in Table 1 . Solventaccessible areas were calculated using MSMS (Sanner et al., 1996) . Superpositions were performed using SSM (Krissinel & Henrick, 2004) . Figures were produced using DINO (Philippsen, 2003) , POVSCRIPT+ (Fenn et al., 2003) , ESPript (Gouet et al., 1999) and UCSF Chimera (Pettersen et al., 2004) .
Results and discussion
Overall structure
The structure of the synthetase domain from human CTPS was determined to a resolution of 2.8 Å (Fig. 2a) . The synthetase domains are arranged within the asymmetric unit in a tetramer with 222 symmetry (Fig. 2b) , as previously observed for the bacterial fulllength enzymes (Endrizzi et al., 2004; Goto et al., 2004) , indicating that the active oligomeric state of the enzyme synthetase domain was crystallized. The structure is a dimer of dimers and three monomers contribute to ligand binding at each active site (Fig. 2b) . This explains the inactivity of the monomeric and dimeric forms, as well as the regulation of oligomerization by nucleotides (Thomas et al., 1988; Pappas et al., 1998) . The tight dimers are formed by subunit pairs AB and CD in the asymmetric unit. As expected from sequence homology (Fig. 2c) , the human CTPS structure is similar to that of bacterial CTPS synthetase domains. A superposition gives r.m.s. deviations for C positions of 1.0 Å for the E. coli enzyme (228 aligned residues, 51% identity) and 1.1 Å for the T. thermophilus CTPS (228 aligned residues, 47% identity). Superposing the different monomers of the tetramer also gives r.m.s. deviations for C positions of 1.0-1.1 Å .
The total change in accessible surface area when going from four monomers to the tetramer can be calculated to be of the order of 7600 Å 2 (1900 Å 2 per monomer). Of this, approximately 900 Å 2 per dimer is buried upon dimer (AB, CD) formation and the remaining 5800 Å 2 is buried by the dimerization of the two dimers.
Regions with missing residues that could not be modelled are located on the same face of CTPS, next to the N-and C-termini. These areas (approximately residues 50-80 and 130-140, depending slightly on the subunit) are likely to form flexible loops and it is possible that they affect ligand binding. The region consisting of residues 131-138 is a loop not present in E. coli CTPS (Fig. 2c ). In the E. coli CTPS structure, the area between residues 50 and 80 of the synthetase domain forms the interface for interacting with the glutaminase domain (Endrizzi et al., 2004) . The N-terminal tag of the recombinant CTPS was also disordered and could not be modelled.
A disulfide bond is present between Cys218 and Cys243 in the structure; this bond is only present in two of the four molecules, monomers A and C, in the asymmetric unit. In monomers B and D the S atoms of these residues are at a distance of 3.9 and 3.5 Å from each other, respectively. These cysteines are not conserved between species and it is uncertain if they play a role in the in vivo function of CTPS.
The active site
The active site of the CTPS synthetase domain is formed by the interaction of three subunits of the tetramer. A cavity with a diameter of 7 Å and a length of 20 Å extends from the active site towards the centre of the tetramer (Fig. 2b) and via this channel all four active sites could be in contact with each other. In the human CTPS structure, two sulfate ions are bound within the active site and they superimpose on the predicted locations of the triphosphate groups of ATP and UTP (Fig. 3) . One of the sulfates (hereafter referred to as SUL-1) is coordinated by the P-loop (residues 12-18) such that it interacts with the backbone N atoms of Gly13, Gly15, Lys16 and Gly17. In this position, binding is also supported by the helix dipole of helix 1 following the P-loop (residues 15-29). In addition, SUL-1 forms a hydrogen bond to the side chain of Lys17. The second sulfate (SUL-2) is found nearby at the interface between two subunits, where it is coordinated by Ser12 from the A subunit and Lys195 and Lys229 from the D monomer. The positions of the sulfates correspond to sites previously shown to bind sulfate in the E. coli and T. thermophilus structures (Endrizzi et al., 2004; Goto et al., 2004) , further highlighting their functional relevance as markers for the substrate phosphate groups.
CTP product feedback inhibition is a well characterized mechanism of CTPS regulation (Long & Pardee, 1967) . Resistance to CTP product inhibition is conferred by mutations in the CTPS coding region in Chinese hamster ovary cells (Whelan et al., 1993) . In the yeast enzyme, Glu161 is involved in this inhibitory mechanism and the E161K mutation increases resistance towards the cancer therapeutic drug CPEC (Ostrander et al., 1998) . In the structure of human CTPS, Glu161 is located at the tetramer interface, making a salt bridge to Arg164. Both of these residues reside in helix 4, the N-terminus of which is involved in CTP binding (Endrizzi et al., 2005) .
Interestingly, a structure of E. coli CTPS complexed with CTP and ADP has recently been solved (Endrizzi et al., 2005) . A superposition of the active sites clearly shows that SUL-1 in human CTPS overlaps with the -phosphate of ADP, while SUL-2 corresponds to the -phosphate of CTP (Fig. 3b ). SUL-2 also marks the binding site for the phosphates in the substrate UTP, whose binding site overlaps with that of CTP. This supports a similar mode of interaction of nucleotides in the human enzyme as in the bacterial protein. However, a detailed description of nucleotide binding in the human enzymes must await the production of crystals without sulfate bound in the active site.
Concluding remarks
We have determined the first crystal structure of human CTPS, a key enzyme in nucleotide biosynthesis and an important drug target. This is the first structure of a CTPS from eukaryotes. In combination with previous structural studies of bacterial enzymes, our data provide a much clearer view of the structure and properties of human CTPS. This information will be of use in functional studies as well as in inhibitor design.
